Sichuan Qingmu Pharmaceutical Co., Ltd.

Sichuan Qingmu Pharmaceutical Co., Ltd., founded in May 2011, is a wholly-owned subsidiary of Chengdu Easton Biopharmaceuticals Co.,Ltd. (Stock code: 688513).

Qingmu is an innovation driven pharmaceutical company with primary strategic focus on the regulated market, the company speciallize in R&D and manufacturing of veterinary APIs.

Focus on business in regulated markets, Qingmu was inspected and approved by US FDA, Korea MFDS, and China NMPA, and also approved by customer audit from China, Europe, USA and Japan, etc.

Please contact us for more discussion:
Sichuan Qingmu Pharmaceutical Co., Ltd.
International Sales Department
Tel: 0086-28-87827187
E-mail: sales@eastonpharma.cn
www.qingmupharm.com

Basic Information
Company Name:	Sichuan Qingmu Pharmaceutical Co., Ltd.
Business Type:	Manufacturer
Product/Services:	API,CDMO,Afoxolaner,Firocoxib?productionService_4=Fluralaner,Maropitant Citrate,Maropitant Base,Oclacitinib Maleate,Sarolaner,Lotilaner,Robenacoxib,
Company Website URL:	TradeNews.html